Regenerative and immunotherapy support for patients in active treatment or recovery — designed to work alongside your primary oncology team. Targeted at immune function, recovery, and quality of life.
By Jed Ryan, Founder and CEO · Reviewed by Adas Darinskas, PhD, Chief Science Officer · Published · Last reviewed
Conventional cancer treatment — surgery, chemotherapy, radiation — relies on chemical and physical agents whose action on cancer cells is rarely fully selective. Healthy tissue takes collateral damage. The immune system, already strained by the disease itself, is further suppressed by the treatment intended to fight it. The clinical question we work on is what can be done alongside conventional care to support the body through and after that treatment.
Immunotherapy is, in this sense, a complementary and bidirectional treatment direction. It can either stimulate an underactive immune system — as in oncology, where the body’s natural response to cancer cells has become insufficient — or suppress an overactive one, as in autoimmune disease. For oncology support, the goal is to strengthen immune response. The tools are biologically active molecules naturally produced by the body, or the body’s own immune cells expanded and activated outside it.
We coordinate adjunctive care for patients in the following contexts:
All treatment decisions are made in coordination with the patient’s primary oncology team. Adjunctive care is layered onto an existing treatment plan, not substituted for one.
Even the best-tolerated cancer treatment puts pressure on systems that the patient still depends on for recovery. The biology behind “treatment fatigue” is concrete:
Adjunctive regenerative care addresses these supporting systems — not the cancer itself — so the body has more capacity to respond to whatever conventional protocol is in progress.
Three primary mechanisms describe how the modalities below work. Each is positioned as supportive of, and complementary to, conventional treatment.
We frame outcomes carefully. The clinical literature on each of these modalities is at varying stages of maturity, and individual response varies widely. We describe mechanisms; we do not promise outcomes; we coordinate every case in conversation with the patient’s oncology team.
Each protocol is designed by Dr. Adas Darinskas in coordination with the patient’s primary oncology team, based on the specific cancer, treatment phase, and individual context. The modalities below are the building blocks most often deployed.
Dendritic cells are the immune system’s antigen-presenting messengers — the cells that train other immune cells to recognize specific threats. In dendritic cell vaccine protocols, the patient’s own dendritic cells are isolated, exposed to tumor-associated antigens outside the body, and reintroduced. The intent is to prime the immune system to recognize and respond to specific cancer cell markers.
An emerging area of clinical investigation in adjunctive oncology care, with a growing body of preclinical and early-phase clinical work supporting its mechanism. Used adjunctively to conventional treatment, never as a replacement.
Natural killer (NK) cells are part of the body’s innate immune surveillance — the population responsible for recognizing and removing abnormal cells. In NK cell therapy, the patient’s NK cells are isolated, expanded in number, and activated using cytokines outside the body, then reinfused.
Peer-reviewed research and ongoing clinical trials are investigating their adjunctive role in oncology care across multiple cancer types. As with all the modalities here, the goal is supportive — layered onto a primary treatment plan, never substituted for one.
Biological therapy uses biologically active molecules naturally produced by the body — cytokines, interferons, and antibodies — to support immune function during and after conventional treatment. These molecules act in the same pathways the body itself uses to coordinate immune response.
Specific protocols are built case by case in coordination with the patient’s oncology team, with the goal of supporting immune capacity through periods when conventional treatment is most depressing it.
Recovery-focused care designed to help the body restore function and reduce side effects following chemotherapy. Includes nutritional, infusion-based, and tissue-recovery support delivered through the partnered clinical setting.
The intent is concrete: faster bone-marrow recovery between cycles, reduced gastrointestinal and mucosal damage, improved energy and cognitive recovery, and broader quality-of-life support during a demanding treatment course.
Physical rehabilitation and movement therapy adapted specifically for patients during and after cancer treatment. Strength, mobility, and recovery of function are addressed deliberately rather than left to general fitness advice.
Delivered by clinicians trained in the specific demands of oncology rehabilitation, with treatment intensity calibrated to where the patient is in their treatment timeline.
Targeted peptide protocols selected to support immune function, energy, recovery, and overall quality of life during and after conventional oncology treatment. The specific peptide stack is built case by case — never generic, always coordinated with the rest of the treatment plan.
The framing here is the same as elsewhere on this page: supportive, adjunctive, and explicit about the boundaries between what regenerative tools can and cannot do.
Every protocol is coordinated with the patient’s oncology team. We do not advise patients to delay, modify, or stop conventional treatment. We provide adjunctive support designed to make conventional treatment more tolerable and recovery more complete.
Strong Craft Regen maintains a continuously updated repository of peer-reviewed research on regenerative medicine — the studies, mechanisms, and ongoing investigations that inform every protocol we coordinate.
Explore the research →